H.C. Wainwright Keeps a Buy Rating on Zynex Inc (ZYXI)


H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Zynex Inc (ZYXI) today and set a price target of $12.00. The company’s shares closed last Monday at $10.78, close to its 52-week high of $11.75.

According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -21.7% and a 25.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aslan Pharmaceuticals Ltd ADR, EyePoint Pharmaceuticals Inc, and Stealth Biotherapeutics Corp.

Currently, the analyst consensus on Zynex Inc is a Moderate Buy with an average price target of $11.40.

See today’s analyst top recommended stocks >>

Zynex Inc’s market cap is currently $349.9M and has a P/E ratio of 37.48. The company has a Price to Book ratio of 24.71.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts